🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07559084
Starting soon Not applicable

Multi-target TMS for Schizophrenia Negative Symptoms

NCT07559084 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Mental Health Center
Phase
Not applicable
Started
2026-10-01
Last updated
2026-09-10

Condition(s) studied

SCHIZOPHRENIA 1 (Disorder)

Investigational drug(s) / intervention(s)

repetitive transcranial magnetic stimulation (rTMS)

repetitive transcranial magnetic stimulation (rTMS): Repetitive transcranial magnetic stimulation (rTMS) is a recently developed neuromodulation technique.

Study summary

This randomized controlled trial (RCT) is the first to evaluate the efficacy and safety of a multi-target TMS protocol targeting the right orbitofrontal cortex (R-OFC), left dorsolateral prefrontal cortex (L-DLPFC), and left inferior parietal lobule (L-IPL) for negative symptoms of schizophrenia.

Eligibility

Sex
ALL
Min age
16 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: 1. Outpatients or inpatients at the Department of Psychiatry, Shanghai Mental Health Center; 2. Meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for first-episode schizophrenia (diagnosed using the Structured Clinical Interview for DSM-5, SCID-5); disease duration less than 5 years at enrollment; 3. Male or female aged 16-45 years; 4. Education duration ≥ 9 years; 5. Stable medication regimen for at least 6 weeks prior to baseline visit and throughout the study period; psychiatric symptoms generally stable within 1 month prior to baseline visit; 6. Participants and their guardians can understand and sign written informed consent; 7. Total score on the PANSS Negative Symptom subscale (PANSS-N) \> 15, and at least one item score ≥ 3. Exclusion Criteria: 1. Current or lifetime psychiatric disorders as determined by SCID-5 assessment; 2. Severe or unstable physical illnesses, including: neurological disorders (delirium, dementia, stroke, epilepsy, migraine, etc.), congestive heart failure, angina pectoris, myocardial infarction, arrhythmia, hypertension, hyperglycemia, malignant tumors, and immunocompromised conditions; 3. Alcohol abuse within 30 days prior to the study or alcohol/drug dependence within 6 months prior to the study; participation in any clinical trial within 30 days prior to baseline; 4. Pregnant or breastfeeding women; 5. Intellectual disability (IQ \< 70); 6. No history of modified electroconvulsive therapy (mECT) within the past 6 months.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shanghai Mental Health Center Shanghai Shanghai Municipality

More Shanghai Mental Health Center trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07559084 on ClinicalTrials.gov ↗ ← All trials in China